Under the High Patronage of
Mr Emmanuel Macron
President of the French Republic
HYBRID 2024
PROGRAM
“NEXT GENERATIONS OF GENE AND CELL THERAPIES”
February 8 and 9, 2024
2 DAYS: 4 SESSIONS
8 FEBRUARY 2024
8 FEBRUARY 20248:00am: Welcome coffee
8:45am: Openning speech Bruno Bonnell, General Secretary for Investment – France 2030 (SGPI)
8:55am: Opening ceremony Thomas Lombes, Deputy CEO for strategy, Inserm, Thierry Hulot, Chairman of Leem, Marc Bonneville, Chairman of Ariis, Rosalie Maurisse, Head of Health - Innovation Department at Bpifrance
Session 1: 9:15am - 12:45pm
The challenges associated with future viral vectors and genome editing approaches.
From the main challenges, avenues and prospects for new vectors to optimized delivery and safety, and tomorrow's genome-editing strategies
9:15am: Overview:
- Oumeya Adjali, Inserm - Gene therapy using AAV viral vectors ; from vector engineering to preclinical evaluation
9:35am: Short talks:
- Ana Buj-Bello, Inserm - Next generation AAV vectors for gene therapy of muscle disorders
- Alexis Duvergé, CNRS - Specific Targeting of Cancer Cells by Lentiviral Vectors
- Maria Grazia Biferi, Spark Therapeutics - Targeting CNS with AAV in a large animal
10:10am: Questions & Answers
10:30am: Coffee break
11:05am: Shortalks:
- Anarita Miccio, Inserm - Genome editing approaches for beta-hemoglobinopathies
- Aurélie Bedel, Bordeaux University - How to secure CRISPR-Cas9 use?
- Stéphane Boissel, Sparing Vision - Pioneering Genomics to Save Sight
11:40am: Questions & Answers
11:55am: Round table:
- Sitra Tauscher-Wisniewski, Novartis
- Anne Douar, Vivet Therapeutics
- Annarita Miccio, Inserm
12:45pm: Lunch break
B2B Meetings: 1:00pm - 3:00pm
Session 2: 3:00pm - 5:30pm
New nucleic acid therapies: applications, vectorization
From prophylactic to therapeutic vaccines and the various potential uses of nucleic acids. Challenges and barriers associated with the uses of nucleic acids: shelf life, route of administration, targeting, etc.
3:00pm: Overview:
- Chantal Pichon, Orleans University - The game changing potential of mRNA-based vaccines and therapeutics
- Pierre Wils, Sanofi - From Innovation to Industrialization: Challenges in Research and Development of mRNA Vaccines
3:35pm:
- Nathalie Mignet, CNRS - Production of lipid nanoparticles formulations for gene and cell therapy
- Philippe Barthélémy, Bordeaux University - Therapeutic oligonucleotides: efficient and specific tools to combat diseases
4:00pm: Questions & Answers
4:15pm: Round table:
- Paul Nioi, Alnylam
- Chantal Pichon, Inserm
- Anette Sommer, Pfizer
- Helène Tran, Servier
- Pierre Wils, Sanofi
B2B Meetings: 5:30pm - 6:30pm
Cocktail reception: 6:30pm - 8:00pm
9 FEBRUARY 2024
8:00am: Welcome coffee
8:30am: Keynote : Cécile Martinat & Christophe Junot - National research program in biotherapies and bioproduction
Session 3: 8:45am - 12:00pm
Immuno cell based therapies
How can the uses of CAR be extended beyond current applications? How can we improve delivery to solid tumours, the role of the tumour environment, survival, etc.? Applications beyond cancer.
8:45am: Overview : Tamas Shisha, Novartis - An Open-label, Multicenter, Phase 1/2 Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323, a CAR-T Cell Therapy Targeting CD19 for Severe Refractory SLE (Preliminary Results)
9:05am: Short talks :
- Mitra Suman, Inserm - Optimizing Adoptive Cellular Therapies in Physio-Chemical Tumor Environments for Superior Anti-Cancer Efficacy without systemic toxicity
- Emmanuel Donnadieu, CNRS - Predicting efficacy and toxicity of CAR T cells using an ex vivo human model
- Marie-Caroline Dieu-Nosjean, Inserm - Manipulation of tertiary lymphoid structures as the third generation of immunotherapy
- Georges Lourenço, Mnemo Therapeutics - A new class of tumor targets for next generation cancer immunotherapies
9:50am: Questions & Answers
10:15am: Coffee break
10:50am: Round table:
- Alessandro Crotta, BMS
- Viggo Van Tendeloo, J&J
- Sante Cundari, Kite - a Gilead compagny
- Karine Rossignol, SmartImmune
- Emmanuel Donnadieu, CNRS
11:40am: Keynote:
- Lise Alter, Head of AIS - The missions of the Health Innovation Agency
12:00pm: Lunch Break
B2B Meetings: 12:00pm - 2:00pm
Session 4: 2:00pm - 4:30pm
Cell therapies and beyond
From the various therapeutic applications of cell therapies to exosomes: how to develop clinical uses of cell therapies, address characterisation issues, etc.? How to take full advantage of the coupling between therapeutic effect and vectorisation properties for exoxomes.
2:00pm: Short talks:
- Louis Casteilla, Toulouse University - MSC-based ATMP: present and future
- Christelle Monville, Evry University - A stem cell therapy pipeline with focus on retinitis pigmentosa and other rare indications with high unmet medical needs
- Frederic Desdouits, Treefrog Therapeutics - Unlocking cell therapy for all
- Christian Jorgensen, CHU of Montpellier - Next generation cell therapies for osteoarticular diseases
2:45pm: Questions & Answers
3:00pm: Overview:
- Philippe Menasché, Paris Cité University - Cell Therapy of Heart Failure: Cells, Exosomes, RNAs?
3:20pm: Short talks:
- Gregory Lavieu, Inserm - Extracellular Vesicle-based vector for targeted therapeutics delivery
- Jeremie Laurent, Astraveus - Lakhesys, the microfluidics powered benchtop factory for cell & gene therapies to develop better products and solve scalability
- Jerome Bonnet, Inserm - Programming bacteria as smart therapeutics
3:50pm: Questions & Answers
4:10pm: Keynote:
- Alain Fischer, Professor at the College of France, President of The French Academy of Sciences
Conclusive Keynote: 4:30pm
Marc Bonneville, Scientific and medical director of Merieux Institut, President of ARIIS
